OLIGOFASTX’s Post

Curious about how Klebsiella aerogenes developed in vivo resistance to clinical available therapies? Take a look of our collaborative work with INIBIC (A Coruña, Spain) published in Antimicrob Agents Chemother 👇 In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC β-lactamase in Klebsiella aerogenes https://lnkd.in/d4zZagJN #resistance #antibiotics #gramnegative #ceftazidime #invivo

Being a pioneer in your field is exciting, but it also comes with some unique challenges. When Alltrna started, there was no pre-existing framework for the production of chemically modified tRNAs. Over the years, the team has pioneered many of the processes and technologies to advance our first engineered tRNA medicines towards the clinic. In this insightful interview with David McCall of BioInsights, our Chief Technology Officer William Kiesman talks about what it is like leading such an innovative team and the processes it has developed, including product synthesis and scaling, proprietary analytical techniques to understand impurity profiles and inform downstream purification steps, and other drug design and quality control steps. He also discusses further advancements the field will need, including: 🔹the use of more ecologically sustainable, enzymatic processes to reduce waste 🔹the ligation of smaller oligonucleotides to make bigger, more complex systems 🔹innovations in oligonucleotide delivery to cells 📚Register for free to read the article in Nucleic Acid Insights: https://lnkd.in/grXYeGcn #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #StopCodonDisease #geneticmedicines #programmablemedicines 

Ready to take your oligonucleotide bioanalysis to the next level? ⏰ Only one day left to register for the live webinar and discover ground-breaking advancements that are redefining precision in oligonucleotide quantitation. Register now for an inside look into novel technologies and methodologies, enabling you to achieve unprecedented accuracy and efficiency in your bioanalytical workflows. Take advantage of the live Q&A session for a chance to get answers to your specific questions. Secure your spot: https://bit.ly/3NSg2un #Bioanalysis #oligonucleotide #bioanalysisandbeyond

Introducing PLXNA1 as a new scaffold protein for engineering extracellular vesicles: in their latest article, Hang Zhao, Libo Zhao at Echo Biotech and collaborators  identified PLXNA1 as a novel scaffold protein that enhances the engineering of EVs by enabling efficient fusion of proteins of interest. The truncated version of PLXNA1 retains the strong EV-sorting capability of its full-length counterpart and supports targeted proteins of interest expression on both the EV surface and within the lumen, either independently or simultaneously https://lnkd.in/eC5SFU7B This approach broadens the criteria for selecting scaffold proteins, highlighting PLXNA1 as a promising tool for advancing therapeutic EV development. An article co-authored by Zhi Li, Da Liu, Jiaxun Zhang, Zhicheng You, Yuzhang Shao, Hongyan Li, Jun Yang, Xiang Liu, Miaozhu Wang, Chengen Wu, Jing Chen, Jianwu Wang and Guanyi Kong #extracellularvesicles #exosomes #bioengineering #scaffoldproteins #Vesiculab

Oncocyte Corporation $OCX dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms #stockstowatch #stocksinnews #investors #daytrader https://lnkd.in/e8atiV63

New #whitepaper alert📜 Read now! Therapeutic peptides are revolutionizing healthcare, but traditional synthesis can be resource-intensive. Our latest white paper, Green Solid Phase Peptide Synthesis (SPPS): An Advanced Approach to Sustainable Peptide Production, explores how we are transforming peptide synthesis through an eco-friendly SPPS method. Mohan Dhote, Chandrakant Kulkarni, Rahul Dudhade, Abhishek Mathur, PhD, MBA #Peptide #GreenChemistry #CDMO

🚨 Must-Read Whitepaper Alert! 🚨 Calling all industrial peptide scientists! Explore our innovative approach to making peptide synthesis greener 🌱. This whitepaper delves into sustainable methods tailored for the industrial manufacturing of therapeutic peptides. Let's lead the way toward a more eco-friendly future in peptide production! #Enzene #GreenPeptideSynthesis #TherapeuticPeptides #Sustainability #Innovation

Over the past twenty years, the field of targeted protein degradation (TPD) has made significant strides as a novel therapeutic approach, utilizing either monovalent agents (molecular glues) or heterobifunctional molecules (PROTACs®). This collection of Best Practices outlines the fundamental principles and methodologies for developing PROTACs®. It includes three sections and a practical case study. 💻 Watch the webinars: https://buff.ly/4fPygsD 🔗 Download the set: https://buff.ly/4131kby

If you want to learn more about PROTACs, check out this excellent work from the EFMC - European Federation for Medicinal Chemistry and Chemical Biology Best Practice team on PROTACs.

Did you know that Pebble's LIVING-KIDNEY system maintains kidneys in a fully functional, physiological state outside the body. Haemodynamics, filtration efficiency, concentration capacity, and electrolyte handling remain completely physiological. Our expertise spans acute kidney injury, drug metabolism, nephrotoxicity screening, ATMP evaluation, tropism/biodistribution studies, and therapeutic safety and efficacy, to name a few. This depth of organ-specific evaluation surpasses in-vivo systems, with studies completed in days, not months, at significantly lower costs and without using laboratory animals. What’s not to like? Explore the LIVING-KIDNEY system's potential for your research – https://lnkd.in/e_psBsPH Pebble Biotechnology Laboratories and The Pebble Institute CIC #KidneyResearch #Glomerulonephritis #Nephrotoxicity #KidneyTransplant #RenalIschaemia #DrugDevelopment #3Rs